Advertisement

Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making

Published:December 09, 2022DOI:https://doi.org/10.1016/j.amjmed.2022.10.021

      Abstract

      Importance

      Although atherosclerosis represents the primary driver of coronary artery disease, evaluation and treatment approaches have historically relied upon indirect markers of atherosclerosis that include surrogates (cholesterol), signs (angina), and sequelae (ischemia) of atherosclerosis. Direct quantification and characterization of atherosclerosis may encourage a precision heart care paradigm that improves diagnosis, risk stratification, therapeutic decision-making, and longitudinal disease tracking in a personalized fashion.

      Observations

      The American College of Cardiology Innovations in Prevention Working Group introduce the Atherosclerosis Treatment Algorithms that personalize medical interventions based upon atherosclerosis findings from coronary computed tomography angiography (CTA) and cardiovascular risk factors. Through integration of coronary CTA-based atherosclerosis evaluation, clinical practice guidelines, and contemporary randomized controlled trial evidence, the Atherosclerosis Treatment Algorithms leverage patient-specific atherosclerosis burden and progression as primary targets for therapeutic intervention. After defining stages of atherosclerosis severity by coronary CTA, Atherosclerosis Treatment Algorithms are described for worsening stages of atherosclerosis for patients with lipid disorders, diabetes, hypertension, obesity, and tobacco use. The authors anticipate a rapid pace of research in the field, and conclude by providing perspectives on future needs that may improve efforts to optimize precision prevention of coronary artery disease. Importantly, the Atherosclerosis Treatment Algorithms are not endorsed by the American College of Cardiology, and should not be interpreted as a statement of American College of Cardiology policy.

      Conclusions and Relevance

      We describe a precision heart care approach that emphasizes atherosclerosis as the primary disease target for evaluation and treatment. To our knowledge, this is the first proposal to use coronary atherosclerosis burden and progression to personalize therapy selection and therapy changes, respectively.

      Disclosure

      The American College of Cardiology Foundation has made an investment in Cleerly, Inc., makers of a software solution that utilizes coronary CT angiography findings to evaluate coronary artery disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andersson C
        • Nayor M
        • Tsao CW
        • Levy D
        • Vasan RS
        Framingham Heart Study: JACC Focus Seminar, 1/8.
        J Am Coll Cardiol. 2021; 77: 2680-2692
        • Arnett DK
        • Blumenthal RS
        • Albert MA
        • et al.
        2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 74: 1376-1414
      1. American College of Cardiology. ASCVD Risk Estimator Plus. Available at: https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/. Accessed October 27, 2022.

        • Virani SS
        • Alonso A
        • Aparicio HJ
        • et al.
        Heart Disease and Stroke Statistics–2021 Update: a report from the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Sachdeva A
        • CP Cannon
        • Deedwania PC
        • et al.
        Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines.
        Am Heart J. 2009; 157 (111-117 e2)
        • Castelli WP
        Lipids, risk factors and ischaemic heart disease.
        Atherosclerosis. 1996; 124: S1-S9
        • Mora S
        • Wenger NK
        • Cook NR
        • et al.
        Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women's Health Initiative.
        JAMA Intern Med. 2018; 178: 1231-1240
        • Akosah KO
        • Schaper A
        • Cogbill C
        • Schoenfeld P
        Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform?.
        J Am Coll Cardiol. 2003; 41: 1475-1479
        • Haffner SM
        • Lehto S
        • Ronnemaa T
        • Pyorala K
        • Laakso M
        Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
        N Engl J Med. 1998; 339: 229-234
        • Muhlestein JB
        • Lappe DL
        • Lima JA
        • et al.
        Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
        JAMA. 2014; 312: 2234-2243
        • Libby P
        The forgotten majority: unfinished business in cardiovascular risk reduction.
        J Am Coll Cardiol. 2005; 46: 1225-1228
        • Vakili D
        • Radenkovic D
        • Chawla S
        • Bhatt DL
        Panomics: new databases for advancing cardiology.
        Front Cardiovasc Med. 2021; 8587768
        • Marwick TH
        • Cho I
        • O Hartaigh B
        • Min JK
        Finding the gatekeeper to the cardiac catheterization laboratory: coronary CT angiography or stress testing?.
        J Am Coll Cardiol. 2015; 65: 2747-2756
        • Schicchi N
        • Fogante M
        • Palumbo P
        • et al.
        The sub-millisievert era in CTCA: the technical basis of the new radiation dose approach.
        Radiol Med. 2020; 125: 1024-1039
        • Newby DE
        • Adamson PD
        • et al.
        • SCOT-HEART Investigators
        Coronary CT angiography and 5-year risk of myocardial infarction.
        N Engl J Med. 2018; 379: 924-933
        • Douglas PS
        • Hoffmann U
        Anatomical versus functional testing for coronary artery disease.
        N Engl J Med. 2015; 373: 91
        • Blankstein R
        • Bittencourt MS
        • Bhatt DL
        Coronary CTA in the evaluation of stable chest pain: clear benefits, but not for all.
        J Am Coll Cardiol. 2017; 69: 1771-1773
        • Knuuti J
        • Wijns W
        • Saraste A
        • et al.
        2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
        Eur Heart J. 2020; 41: 407-477
      2. National Institute for Health and Care Excellence (NICE). NICE Guidance for Stable Chest Pain Patients (CG95 & MTG32) to Appropriately Diagnose Patients with Suspected Coronary Artery Disease. Available at: https://www.nice.org.uk/sharedlearning/nice-guidance-for-stable-chest-pain-patients-cg95-mtg32-to-appropriately-diagnose-patients-with-suspected-coronary-artery. Accessed October 27, 2022.

      3. Saleh M, Ambrose JA. Understanding myocardial infarction. F1000Res. 2018;7:F1000 Faculty Rev-1378. Ecollection 2018. doi:10.12688/f1000research.15096.1.

        • Fischer C
        • Hulten E
        • Belur P
        • Smith R
        • Voros S
        • Villines TC
        Coronary computed tomographyangiography versus intravascular ultrasound for estimation of coronary stenosis and atherosclerotic plaque burden: a meta-analysis.
        J Cardiovasc Comput Tomogr. 2013; 7: 256-266
        • de Graaf MA
        • Broersen A
        • Kitslaar PH
        • et al.
        Automatic quantification and characterization of coronary atherosclerosis with computed tomography coronary angiography: cross-correlation with intravascular ultrasound virtual histology.
        Int J Cardiovasc Imaging. 2013; 29: 1177-1190
        • van Velzen JE
        • Schuijf JD
        • de Graaf FR
        • et al.
        Plaque type and composition as evaluated non-invasively by MSCT angiography and invasively by VH IVUS in relation to the degree of stenosis.
        Heart. 2009; 95: 1990-1996
        • Hadamitzky M
        • Achenbach S
        • Al-Mallah M
        • et al.
        Optimized prognostic score for coronary computed tomographic angiography: results from the CONFIRM registry (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter Registry).
        J Am Coll Cardiol. 2013; 62: 468-476
        • Min JK
        • Budoff MJ
        • Bax JJ
        The multidimensionality of coronary artery disease: combining, conflating, and changing.
        JACC Asia. 2021; 1: 49-52
        • Yang S
        • Lee JM
        • Hoshino M
        • et al.
        Prognostic implications of comprehensive whole vessel plaque quantification using coronary computed tomography angiography.
        JACC Asia. 2021; 1: 37-48
        • Chang HJ
        • Lin FY
        • Lee SE
        • et al.
        Coronary atherosclerotic precursors of acute coronary syndromes.
        J Am Coll Cardiol. 2018; 71: 2511-2522
        • Ferencik M
        • Mayrhofer T
        • Bittner DO
        • et al.
        Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial.
        JAMA Cardiol. 2018; 3: 144-152
        • Williams MC
        • Kwiecinski J
        • Doris M
        • et al.
        Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction: results from the multicenter SCOT-HEART trial (Scottish Computed Tomography of the HEART).
        Circulation. 2020; 141: 1452-1462
        • Taron J
        • Foldyna B
        • Mayrhofer T
        • et al.
        Risk stratification with the use of coronary computed tomographic angiography in patients with nonobstructive coronary artery disease.
        JACC Cardiovasc Imaging. 2021; 14: 2186-2195
        • van Rosendael AR
        • Narula J
        • Lin FY
        • et al.
        Association of high-density calcified 1K plaque with risk of acute coronary syndrome.
        JAMA Cardiol. 2020; 5: 282-290
        • Abdelrahman KM
        • Chen MY
        • Dey AK
        • et al.
        Coronary computed tomography angiography from clinical uses to emerging technologies: JACC state-of-the-art review.
        J Am Coll Cardiol. 2020; 76: 1226-1243
        • Stuijfzand WJ
        • van Rosendael AR
        • Lin FY
        • et al.
        Stress myocardial perfusion imaging vs coronary computed tomographic angiography for diagnosis of invasive vessel-specific coronary physiology: predictive modeling results from the computed tomographic evaluation of atherosclerotic determinants of myocardial ischemia (CREDENCE) trial.
        JAMA Cardiol. 2020; 5: 1338-1348
        • Motoyama S
        • Ito H
        • Sarai M
        • et al.
        Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up.
        J Am Coll Cardiol. 2015; 66: 337-346
        • Lee SE
        • Chang HJ
        • Sung JM
        • et al.
        Effects of statins on coronary atherosclerotic plaques: the PARADIGM study.
        JACC Cardiovasc Imaging. 2018; 11: 1475-1484
        • van Rosendael AR
        • Lin FY
        • van den Hoogen IJ
        • et al.
        Progression of whole-heart atherosclerosis by coronary CT and major adverse cardiovascular events.
        J Cardiovasc Comput Tomogr. 2021; 15: 322-330
        • Budoff MJ
        • Bhatt DL
        • Kinninger A
        • et al.
        Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
        Eur Heart J. 2020; 41: 3925-3932
        • Budoff MJ
        • Muhlestein JB
        • Bhatt DL
        • et al.
        Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
        Cardiovasc Res. 2021; 117: 1070-1077
        • Hirai K
        • Imamura S
        • Hirai A
        • Ookawara S
        • Morishita Y
        Effect of evolocumab on vulnerable coronary plaques: a serial coronary computed tomography angiography study.
        J Clin Med. 2020; 9: 3338
        • Henzel J
        • Kepka C
        • Kruk M
        • et al.
        High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study.
        JACC Cardiovasc Imaging. 2021; 14: 1192-1202
        • Vaidya K
        • Arnott C
        • Martinez GJ
        • et al.
        Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study.
        JACC Cardiovasc Imaging. 2018; 11: 305-316
        • Greenland P
        • Blaha MJ
        • Budoff MJ
        • Erbel R
        • Watson KE
        Coronary calcium score and cardiovascular risk.
        J Am Coll Cardiol. 2018; 72: 434-447
        • Lauby-Secretan B
        • Loomis D
        • Straif K
        Breast-cancer screening–viewpoint of the IARC Working Group.
        N Engl J Med. 2015; 373: 1479
        • Lauby-Secretan B
        • Vilahur N
        • Bianchini F
        • Guha N
        • Straif K
        • International Agency for Research on Cancer Handbook Working Group
        The IARC perspective on colorectal cancer screening.
        N Engl J Med. 2018; 378: 1734-1740
        • Aberle DR
        • Adams AM
        • et al.
        • National Lung Screening Trial Research Team
        Reduced lung-cancer mortality with low-dose computed tomographic screening.
        N Engl J Med. 2011; 365: 395-409
        • Min JK
        • Dunning A
        • Lin FY
        • et al.
        Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease.
        J Am Coll Cardiol. 2011; 58: 849-860
        • van Rosendael AR
        • Lin FY
        • Ma X
        • et al.
        Percent atheroma volume: optimal variable to report whole-heart atherosclerotic plaque burden with coronary CTA, the PARADIGM study.
        J Cardiovasc Comput Tomogr. 2020; 14: 400-406
        • Budoff M
        • Lakshmanan S
        • Bhatt DL
        The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.
        Eur Heart J. 2021; 42: 3025-3026
        • Bhatt DL
        • Steg PG
        • Miller M
        • et al.
        Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
        N Engl J Med. 2019; 380: 11-22
        • Watanabe T
        • Ando K
        • Daidoji H
        • et al.
        A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
        J Cardiol. 2017; 70: 537-544
        • Shapiro MD
        • Bhatt DL
        “Cholesterol-Years” for ASCVD risk prediction and treatment.
        J Am Coll Cardiol. 2020; 76: 1517-1520
        • Lawler PR
        • Bhatt DL
        • Godoy LC
        • et al.
        Targeting cardiovascular inflammation: next steps in clinical translation.
        Eur Heart J. 2021; 42: 113-131
        • Sabatine MS
        • Giugliano RP
        • Pedersen TR
        Evolocumab in patients with cardiovascular disease.
        N Engl J Med. 2017; 377: 787-788
        • Schwartz GG
        • Steg PG
        • Szarek M
        • et al.
        Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N Engl J Med. 2018; 379: 2097-2107
        • Ray KK
        • Bays HE
        • Catapano AL
        • et al.
        Safety and efficacy of bempedoic acid to reduce LDL cholesterol.
        N Engl J Med. 2019; 380: 1022-1032
        • Ray KK
        • Wright RS
        • Kallend D
        • et al.
        Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.
        N Engl J Med. 2020; 382: 1507-1519
        • Eikelboom JW
        • Connolly SJ
        • Yusuf S
        Rivaroxaban in stable cardiovascular disease.
        N Engl J Med. 2018; 378: 397-398
        • Nidorf SM
        • Fiolet ATL
        • Mosterd A
        • et al.
        Colchicine in patients with chronic coronary disease.
        N Engl J Med. 2020; 383: 1838-1847
        • Marso SP
        • Bain SC
        • Consoli A
        • et al.
        Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.
        N Engl J Med. 2016; 375: 1834-1844
        • Marso SP
        • Daniels GH
        • Brown-Frandsen K
        • et al.
        Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322
        • Holman RR
        • Bethel MA
        • Hernandez AF
        Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2017; 377: 2502
        • Holman RR
        • Bethel MA
        • Mentz RJ
        • et al.
        Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2017; 377: 1228-1239
        • Gerstein HC
        • Colhoun HM
        • Dagenais GR
        • et al.
        Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
        Lancet. 2019; 394: 121-130
        • Zinman B
        • Wanner C
        • Lachin JM
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Wiviott SD
        • Raz I
        • Bonaca MP
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Neal B
        • Perkovic V
        • Mahaffey KW
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Bhatt DL
        • Szarek M
        • Steg PG
        • et al.
        Sotagliflozin in patients with diabetes and recent worsening heart failure.
        N Engl J Med. 2021; 384: 117-128
        • Pfeffer MA
        • Claggett B
        • Diaz R
        • et al.
        Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.
        N Engl J Med. 2015; 373: 2247-2257
        • Pareek M
        • Schauer PR
        • Kaplan LM
        • Leiter LA
        • Rubino F
        • Bhatt DL
        Metabolic surgery: weight loss, diabetes, and beyond.
        J Am Coll Cardiol. 2018; 71: 670-687
        • Ahmadi A
        • Argulian E
        • Leipsic J
        • Newby DE
        • Narula J
        From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review.
        J Am Coll Cardiol. 2019; 74: 1608-1617
        • Mori H
        • Torii S
        • Kutyna M
        • Sakamoto A
        • Finn AV
        • Virmani R
        Coronary artery calcification and its progression: what does it really mean?.
        JACC Cardiovasc Imaging. 2018; 11: 127-142
        • Ko DT
        • Khan AM
        • Kotrri G
        • et al.
        Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study.
        J Am Heart Assoc. 2018; 7e010007
        • Salami JA
        • Warraich H
        • Valero-Elizondo J
        • et al.
        National trends in statin use and ein the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey.
        JAMA Cardiol. 2017; 2: 56-65
        • Akyea RK
        • Kai J
        • Qureshi N
        • Iyen B
        • Weng SF
        LDL cholesterol response to statins and future risk of cardiovascular disease.
        Heart. 2019; 105: 1290-1291
        • Caparrotta TM
        • Blackbourn LAK
        • McGurnaghan SJ
        • et al.
        Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland.
        Diabetes Care. 2020; 43: 2034-2041
        • Casalino LP
        • Nicholson S
        • Gans DN
        • et al.
        What does it cost physician practices to interact with health insurance plans?.
        Health Aff (Millwood). 2009; 28: w533-w543
      4. Min JK, Chang HJ, Andreini D, et al. Coronary CTA plaque volume severity stages according to invasive coronary angiography and FFR. J Cardiovasc Comput Tomogr. 2022;16(5):415–422.